Interim statement of progress with Simdax according to a confirmation by Abbott today

In accordance with the confirmation received today by Orion Corporation from Abbott Laboratories, the license holder of levosimendan (Simdax), the information given in Orion's earlier publications, such as the Interim Reports, about the estimated regulatory timelines for levosimendan is updated as follows: Abbott is currently in the process of finalising the data analysis and is in discussions with U.S. and European regulators. Abbott will not be filing a regulatory application for the product in 2005. Abbott will inform about timelines for further actions as soon as possible. Orion Corporation Jukka Viinanen Olli Huotari President and CEO General Counsel Contact persons: Jukka Viinanen, President and CEO, Orion Corporation, phone +358 10 429 3710 Anne Allo, VP, Investor Relations, phone +358 10 429 3735, gsm +358 50 429 3735 Distribution: Helsinki Exchanges Media Publisher: Orion Corporation Corporate Administration Orionintie 1A, 02200 Espoo Homepage: www.orion.fi

The release as fetched from its publisher. orionpharma.com ↗